• Greenlight Biosciences

  Participated · Series D · Sep 2017

  GreenLight Biosciences develops low-cost, scalable RNA products using a patented, cell-free bioprocessing platform to enable commercial RNA applications in agriculture and life sciences. The company aims to commercialize a pipeline of RNA-based agricultural biocontrols and expand into RNA-based therapeutics and vaccines. Its platform dramatically lowers RNA production costs, enabling products that previously were not commercially viable. GreenLight expects its first biopesticide to launch in 2022 and is pursuing a commercially available mRNA-based COVID-19 vaccine. The company highlights applications across plant, human, and animal health and emphasizes environmentally friendly crop protection that avoids residues and spares beneficial insects. GreenLight Biosciences is a Boston-based biotech that specializes in producing messenger RNA (mRNA) for vaccines. The company is focused on scaling mRNA manufacturing capacity to support the creation of "billions of doses" of potential COVID-19 vaccines for trials and potential deployment. GreenLight is also developing several versions of its own mRNA-based vaccine candidates targeting SARS-CoV-2. Some of the new funding will be used both to expand production capacity and to advance those vaccine candidates. The article characterizes mRNA vaccines as a relatively novel approach that contain no actual virus and can shorten pre-clinical development timelines. GreenLight raised special-purpose funding to support these manufacturing and development efforts. GreenLight Biosciences develops RNA products for plant and life science applications, focusing on agricultural bio-control products and human and animal vaccines and therapeutics. The company collaborates with industry leaders and academic institutions to advance vaccine development, pandemic preparation, crop management, and plant protection. Led by Co-Founder and CEO Andrey Zarur, GreenLight is expanding its discovery and development capabilities across multiple segments. The firm operates Plant Sciences R&D in RTP, NC and St. Louis, MO. Management says the work spans a portfolio of bio-performance candidates for plant and life sciences. The company intends to accelerate development through existing partnerships and the newly raised capital. GreenLight Biosciences develops RNA-based products for agriculture using its Cell-Free Bioprocessing® platform. The company focuses on dsRNA molecules designed to directly target insect and viral pests in high-value crops while sparing beneficial organisms and minimizing environmental impact. It is also developing additional RNA offerings in public health, vaccine development and human therapeutics. Led by Co-Founder and CEO Andrey J. Zarur, Ph.D., GreenLight plans to use new capital to accelerate development and field testing of several dsRNA molecules and to build up its team. The company recently completed a Series D financing and is based in Medford, Mass. GreenLight Biosciences is a Medford, Mass.-based developer of a cell-free approach to microbial chemical production. The company builds a bio-based manufacturing platform to produce chemicals from renewable, non-petroleum resources. Its core technology focuses on cell-free production methods intended to enable cleaner, scalable chemical manufacturing. GreenLight is led by Andrey Zarur, Ph.D., Co-Founder, CEO and Chairman. Financially, the company completed a Series C financing in July 2015; the amount was undisclosed. The round included participation from both new and existing investors and was led by MLS Capital Fund II.

• Newforma

  Participated · Series D · Aug 2013

  Newforma is a Manchester, NH-based project information management (PIM) software company that provides solutions for architects, engineers, construction firms and owners. It offers tools to search project data, manage massive amounts of project email, securely share information among companies on a project, and provide a full audit trail to mitigate risk. The company recently released the tenth edition of its solution, which supports on-premise deployments, cloud hosting, and a suite of mobile apps for smartphones and tablets. Its products are used by 1,000 organizations. Newforma plans to use the Series D proceeds to develop new products and expand into new geographic markets. The company is led by CEO Ian Howell.

• Allegro Diagnostics

  Led · Series A · Jul 2011

  Allegro Diagnostics, based in Maynard, Mass., has developed a molecular testing platform that uses gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. The platform is based on the "field of injury" principle and detects gene expression signatures in non-malignant airway cells of current and former smokers that indicate malignancy elsewhere in the lung. The company's lead product is the BronchoGen™ genomic test, intended for use alongside standard bronchoscopy to provide additional diagnostic information earlier in the diagnostic process. Allegro has applied its platform to generate multiple product candidates and plans to commercialize BronchoGen in 2012. The company closed a $5.4M Series A extension financing, and proceeds from the round will support BronchoGen's commercialization. Approximately 300,000 bronchoscopic exams are performed each year and many results are inconclusive, which Allegro positions BronchoGen to address clinically and commercially. Allegro Diagnostics develops and commercializes molecular diagnostics for lung cancer using proprietary gene expression technology originating at the Pulmonary Center of Boston University School of Medicine. The company was founded in 2006 and is based in Boston. Its initial product is intended to provide earlier, less invasive and more accurate diagnosis of early-stage lung cancer and will be taken into the clinic following this financing. Jerome Brody, MD, a developer of the underlying technology, has joined Allegro as Chief Scientific Officer. Allegro is privately funded by Kodiak Venture Partners, Catalyst Health Ventures, and Boston University. The Series A proceeds are intended to enable clinical development and commercialization of the company’s first diagnostic.

• ideeli

  Participated · Series C · Apr 2011

  Ideeli is a flash-sales e-commerce site that offers 50 to 70 percent discounts on clothing, accessories and home goods during limited multi-day sales. Launched in 2007, the site had over 5 million members at last count. Products include clothing for men, women and children, as well as jewelry, handbags and home accessories. In 2011 Ideeli reported $77.7 million in revenue. Last year the company announced $30 million in new funding to expand beyond the flash-sales model. The company recently raised an additional $12 million (confirmed after an SEC filing), but it is unclear who participated in this latest round, and the article notes uncertainty about continued growth as the flash-sales model has faltered. Ideeli operates a private, members-only flash sales platform that offers 50–70% discounts on clothing, accessories and home items over multi-day sales events. The site serves over 4 million members, with upcoming sales announced via email. Product categories include apparel for men, women and children, jewelry, handbags and home accessories. Ideeli has expanded into travel and daily deals, broadening its offerings beyond merchandise. The company says the new financing will be used for category expansions, partnerships, technology enhancements, marketing, hiring and improving the member experience. Ideeli was founded in 2007 and has raised nearly $70 million in total funding to date. Ideeli operates a members-only sample-sale shopping site that runs private, time-limited sales where designers place excess inventory at roughly 50–70% discounts. Sales are invite-only or available by request and are announced to members via email. Product categories include clothing for men, women and children, as well as jewelry, handbags and home accessories. The company said it recently hit one million members and was set to do $50 million in revenue this year, with CEO Paul Hurley projecting $175 million next year. Ideeli was founded in 2007. The article situates Ideeli among other fast-growing online sample-sale startups such as Gilt Groupe and Hautelook, noting strong investor and retail interest in the category.

• AppNexus

  Participated · Series C · Oct 2010

  AppNexus operates a powerful, real-time decisioning platform that supports products for publishers to maximize yield and for marketers and agencies to harness data and machine learning to deliver customized campaigns. The company offers a full suite of advertising-technology products, including an SSP and Yieldex Analytics. AppNexus is headquartered in New York City and employs over 1,000 professionals across five continents. It recently entered a strategic partnership with News Corp that will make AppNexus' full suite available to several News Corp businesses, including Dow Jones, News UK and News Corp Australia. AppNexus also augments its existing relationship with Unruly; under that partnership buyers and sellers of outstream inventory can combine AppNexus' video buying platform with Unruly's UnrulyX SSP (70% of views delivered across comScore 500 sites). The company emphasized long-term innovation and digital expansion through strategic media partnerships. AppNexus has built a platform for buying and selling ads through real-time bidding. The company says 30 billion ad impressions are transacted on the platform each day and more than $1 billion in ad spend ran through the platform in 2013. AppNexus employs nearly 600 people. The company announced an additional $60M funding round (which could eventually reach $100M) at a $1.2B valuation. CEO Brian O'Kelley said AppNexus just saw its first profitable quarter and that recent weak public-market performance by ad-tech companies did not factor into the decision to raise capital. The new funding brings total capital invested in the company to just over $200M. AppNexus runs a real-time bidding platform that powers ad networks and programmatic advertising transactions. The company is led by co-founder and CEO Brian O’Kelley, who previously built the ad exchange platform at Right Media. AppNexus reported managing about $700 million of advertising spend in 2012 and said it nearly tripled its revenues that year. The business has grown to more than 400 employees across nine offices worldwide. The new funding was announced following what the company described as a successful year. AppNexus builds a realtime bidding platform and management tools that allow ad networks to interface with large display advertising exchanges. The service connects roughly 120 ad networks to exchanges such as Google Ad Exchange, Microsoft Media Network, Admeld, OpenX, and AdECN. The platform helps advertisers and networks optimize for metrics like cost-per-click and cost-per-impression. More than 4 billion ad impressions are served through AppNexus every day, up from zero two years prior. The company has rapidly grown headcount, increasing from about 23 employees at the start of the year to roughly 65. CEO Brian O’Kelley said the company has “gone crazy on the revenue side,” though he declined to disclose specific revenue figures. AppNexus is a New York City-based provider of a platform for buying real-time online advertising. Its core product gives buyers of online ads a proprietary gateway to leading ad exchanges and ad inventory aggregators. On October 11, 2009, the company announced it secured a $5 million equity financing. The round was led by existing investor Kodiak Venture Partners, with participation from current investors Venrock and First Round Capital. Proceeds will be used to continue expanding the business and to add top industry talent. The financing is intended to support growth of its real-time ad-buying platform.

No current team members are available.